Latest News – PSNC Main site
Pharmaceutical Services Negotiating Committee
Update on new flexible approaches to flu vaccination service
An update on the new flexible approaches being considered for support the provision of the flu vaccination service has been released. Contractors must note that the changes PSNC is seeking to the flu vaccination service, described in the update, have not yet been agreed and may never be agreed. On 3rd July 2020, PSNC published...
Further additions made to July 2020 Price Concessions
The Department of Health and Social Care (DHSC) has today granted three additional price concessions for prescriptions dispensed and submitted for payment in July 2020 only. Following the publication of the July final price concession update on 30th July 2020, PSNC made an additional application for three further price concessions. This was based on feedback received from...
Supply Notification: Sulfasalazine 250mg/5ml oral suspension sugar free (Rosemont) – Update
Update 07/08/2020 resupply date now expected end Sept 2020 Department of Health and Social Care (DHSC) has issued a medicine supply notification for Sulfasalazine 250mg/5ml oral suspension sugar free (Rosemont) . Sulfasalazine 250mg/5ml oral suspension sugar free (Rosemont) is out of stock until August 2020. Sulfasalazine 500mg tablets remain available. Some specials manufacturers are able...
Medicine Supply Notification: Pethidine 50mg tablets
Department of Health and Social Care (DHSC) has issued a medicine supply notification for Pethidine 50mg tablets Martindale are out of stock of Pethidine 50mg tablets Supplies are currently available from Teva although they will be out of stock by the end of August. There are no alternative suppliers. Neither company are currently able to...
Initial information on the Part 2 PQS for 2020/21
An initial outline of requirements for Part 2 of the 2020/21 Pharmacy Quality Scheme (PQS) has been released. On 13th July 2020, PSNC informed contractors that a new PQS for the first part of 2020/21 had been launched. The focus of the first part of the scheme was to ensure community pharmacy contractors and their...
Rollout of EPS Phase 4 for SystmOne and EMIS prescribers
NHS Digital is supporting rollout of EPS Phase 4 to many more practices to support patients in getting their medicines during what is expected to be a busy winter season for healthcare providers. Under Phase 4 electronic prescriptions become the default, thereby reducing the amount of paperwork generated and making the process more COVID-safe. Around...
Further details on the national flu immunisation programme announced
Further to the Annual flu letter published on the 14th May 2020, the Department of Health and Social Care (DHSC), Public Health England (PHE) and, NHS England and NHS Improvement (NHSE&I) have jointly published a second letter to provide further information on the national flu immunisation programme for 2020/21. The letter highlights the risk of possible co-circulation of COVID-19 and flu this winter. As...
Reported drug quota issues – update
PSNC is urging community pharmacy teams to continue to report issues obtaining stock due to drug quota allocations and contingency arrangements applied by wholesalers and/or manufacturers not only to help with our investigation into wider quota issue(s) affecting the supply chain but also to assist with our representation work on these matters. Since the launch of the quota...
Brexit: DHSC plans for end of Transition Period
The Department of Health and Social Care (DHSC) has clarified its plans for the continuity of supply of medicines and medical goods after the end of the Brexit Transition Period. In a letter to suppliers of medicines and medicinal products, DHSC’s Chief Commercial Officer Steve Oldfield set out the Government’s preparations alongside its expectations of...
Class 2 Medicines recall: Clexane 4,000 IU (40mg) /0.4ml Syringes (Pharmaram Ltd)
Class 2 MHRA medicines recall – Clexane 4,000 IU (40mg) /0.4ml Syringes (Pharmaram Ltd) PLPI 33652/0067 Drug alert number: EL (20)A/37 Date issued: 04 August 2020 The Medicines and Health products Regulatory Agency (MHRA) has issued a class 2 medicines recall for: Clexane 4,000 IU (40mg) /0.4ml Syringes (Pharmaram Ltd) PLPI 33652/0067 Pharmaram Ltd has...
PharmaTimes: PharmaTimes Website RSS
PharmaTimes - The latest news in healthcare and life sciences - PharmaTimes Website RSS
Researchers say hydroxychloroquine could still prevent COVID-19
Scientists from the University of Oxford say the drug is being ‘discarded prematurely’
EU approves new indication for Novartis’ Xolair
Allergy drug approved for severe chronic rhinosinusitis with nasal polyps
Second COVID-19 peak in the UK can be avoided with testing and tracing, study finds
Study co-led by UCL and the London School of Hygiene & Tropical Medicine
GSK’s anti-BCMA drug Blenrep wins US approval
First anti-BCMA therapy to be approved anywhere in the world
AZ’s Fasenra study confirms robust efficacy in eosinophilic asthma
Drug reduced annual rate of asthma exacerbations by 49%
UCB’s Cimzia bags EU label extension
Drug is first biologic in Europe to be approved with a dose reduction label for axSpA patients
NICE updates guidance on chronic pain treatments
Draft guidance says some commonly used drug treatments should be avoided
Novavax’s COVID-19 vaccine produces immune response in early study
Vaccine was generally well-tolerated with only a few mild side-effects reported
Novartis’ CAR-T therapy Kymriah hits endpoint in follicular lymphoma trial
Company expect to file regulatory submissions in 2021
Pharma’s reputation has climbed during COVID-19 pandemic, study finds
Roche, AstraZeneca, Novo Nordisk and Sanofi all climbed index rankings
AstraZeneca forges licensing agreement with Redx Pharma
AZ will pay $17m in early milestone payments for the UK biotech’s fibrotic asset
NHS adapts to pandemic with ‘COVID-friendly’ cancer treatments
Health service extends access to at-home treatments to reduce patients' risk of contracting coronavirus
Janssen’s depression nasal spray Spravato bags new FDA approval
Drug approved to treat major depressive disorder with acute suicidal ideation or behaviour
Oxford Biomedica and Beam Therapeutics sign CAR-T deal
Agreement will utilise Oxford Biomedica's LentiVector platform
Roche’s tumour-agnostic therapy Rozlytrek approved in EU
Therapy has been approved to treat advanced NTRK fusion-positive solid tumours
Every sector of the pharmaceutical market is represented under one roof, this year in Madrid. Attending CPhI Worldwide is the most cost effective way to establish new business relationships, meet with global partners and stay updated on the latest industry trends.
Find out more: https://www.cphi.com/europe/